POSTER PRESENTATION



Open Access

Oxygen-enhanced MRI can accurately identify, quantify and map tumour hypoxia in preclinical models

JPB O'Connor^{*}, JKR Boult, Y Jamin, M Babur, KG Finegan, KJ Williams, AR Reynolds, RA Little, A Jackson, GJM Parker, JC Waterton, SP Robinson

From International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015) London, UK. 5-7 October 2015

Aim

There is need for non-invasive methods to identify, quantify and map tumour hypoxia. In this study we used an emerging technology – R_1 oxygen enhanced MRI (OE-MRI) – to distinguish those tumour sub-regions that respond to hyperoxic gas challenge from refractory sub-regions. We hypothesised that the proportion of refractory tumour tissue (Oxy-R) would be a robust biomarker of tumour hypoxia across multiple models with different vascular and hypoxic phenotypes.

Methods: OE-MRI signal precision, stability and relationship to tissue pO_2 were evaluated in well vascularised renal cancer 786-O xenografts. Dynamic sensitivity of proportional Oxy-R to acute changes in hypoxia was evaluated using hydralazine challenge. Relationship of proportional Oxy-R to tissue immunohistochemistry and gadolinium DCE-MRI were explored in parental and drug-resistant 786-O models and in SW620 xenografts.

Results

Phantom and *in vivo* experiments demonstrated the accuracy, precision and stability of R_1 measurement. The proportion of tumour Oxy-R increased significantly following hydralazine challenge (p=0.045) relative to control. The proportion of tumour with perfused Oxy-R voxels was correlated to chronic hypoxia in well perfused 786-O-R xenografts(rho 0.810, p=0.028) and in relatively necrotic SW620 xenografts (rho 0.929, p=0.002).

* Correspondence: james.oconnor@manchester.ac.uk

University of Manchester, Oxford Road, Manchester, M13 9PL, UK

Conclusion

The proportion of tumour perfused Oxy-R is a robust biomarker of tumour hypoxia. Voxel-wise analysis of dual oxygen and gadolinium challenge has potential to quantify and map tumour hypoxia as prognostic, predictive and pharmacodynamic biomarkers that could facilitate personalised healthcare.

Published: 2 October 2015

doi:10.1186/1470-7330-15-S1-P9 Cite this article as: O'Connor *et al.*: Oxygen-enhanced MRI can accurately identify, quantify and map tumour hypoxia in preclinical models. *Cancer Imaging* 2015 15(Suppl 1):P9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2015 O'Connor et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.